Sustaining Vision: Empowering Optometry for Tomorrow’s Retinal Care

DISCLOSURE POLICY
In accordance with the COPE Standards for Integrity and Independence, it is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that have identified and mitigated financial relationships and conflicts of interest to ensure independence, objectivity, balance, and scientific accuracy prior to this educational activity. 

The following faculty/staff members have reported financial relationships with ineligible companies within the last 24 months.

Arshad M. Khanani, MD, MA, FASRS, has had a financial relationship or affiliation with the following ineligible companies in the form of Advisory Board: Oculis. Consultant: 4DMT, AbbVie, Adverum Biotechnologies, Alcon, Amgen, Annexin, Annexon, Apellis Pharmaceuticals, Aviceda Therapeutics, Beacon Therapeutics, Boehringer Ingelheim, Clearside Biomedical, Complement Therapeutics, Exegenesis, EyePoint Pharmaceuticals, Frontera Therapeutics, Genentech, Gyroscope Therapeutics, i-Lumen Scientific, Iveric Bio, Janssen Pharmaceuticals, Kodiak Sciences, Kriya Therapeutics, Nanoscope, Novartis, Ocular Therapeutix, Oculis, Ocuphire, OcuTerra, Olive BioPharma, Opthea, Oxular, Oxurion, Perfuse, PolyPhotonix, Ray Therapeutics, Recens Medical, Regeneron, Regenxbio, Revive, RevOpsis, Roche, Sanofi, Stealth BioTherapeutics, Théa Pharma, Unity Biotechnology, Vanotech, and Vial. Grant/Research Support: 4DMT, Aviceda, Adverum Biotechnologies, Alexion, Annexon, Apellis Pharmaceuticals, Aviceda Therapeutics, EyePoint Pharmaceuticals, Exegenesis, Genentech, Gyroscope Therapeutics, Iveric Bio, Janssen, Kodiak Sciences, Neurotech, Ocular Therapeutix, Oxular, and Regenxbio. Common Stock: Oculis and Opthea.  

Veeral Sheth, MD, MBA, FASRS, FACS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alkeus, Apellis Pharmaceuticals, Boehringer Ingelheim, EyePoint Pharmaceuticals, Genentech, Iveric Bio, Janssen, Kriya Therapeutics, Novartis, Ocular Therapeutix, Oculis, Ocuphire, Ollin Biosciences, Opthea, Regeneron, RevOpsis, Unity, and Vial. Grant/Research Support: 4DMT, AbbVie, Adverum Biotechnologies, Alimera Sciences, Ashvattha Therapeutics, Astellas, Aviceda, Chengdu Kanghong, Eluminex Biosciences, Eyebiotech, EyePoint Pharmaceuticals, Genentech, Gyroscope Therapeutics, i-Lumen Scientific, Ionis, Iveric Bio, Janssen Pharmaceuticals, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Oculus, Ocugen, OcuTerra, Olix, Opthea, Outlook, Oxular, Oxurion, Perfuse Therapeutics, Recens Medical, Regeneron, Regenxbio, Rezolute, Roche, SalutarisMD, SamChungDang, Santen, Smilebiotek, Unity Biotechnology, and Vanotech. Speaker's Bureau: Genentech and Iveric Bio.

Lejla Vajzovic, MD, FASRS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie/Allergan, Adverum Biotechnologies, Alcon, Alimera Sciences, Alkeus, Apellis Pharmaceuticals, Astellas, Bausch + Lomb, BioCryst, BMC Medical Education, BVI, Clearside Biomedical, CoherusBiosciences, DORC, Evolve Medical Education, Genentech, Guidepoint, Gyroscope Therapeutics, Iveric Bio, Janssen/Johnson & Johnson Vision, Lexitas, Nanoscope, Novartis, Ocugen, Ocular Therapeutix, Ocular Surgical, OcuTerra, ONL Therapeutics, Outlook Therapeutics, Regenxbio, Roche, and Vindico Medical Education. Grant/Research Support: AbbVie/Allergan, AGTC, Alcon, Aldeyra, Apellis Pharmaceuticals, Genentech, Gyroscope Therapeutics, Heidelberg Engineering, Janssen/Johnson & Johnson Vision, National Eye Institute, Novartis, Ocugen, Ocular Therapeutix, Optos, Regenxbio, and Roche. Patents/Royalties: Alcon.

The Evolve staff, planners, and peer reviewer have no financial relationships with ineligible companies.